AMG 133 is a bispecific molecule that addresses two targets, GLP-1 and GIPR, and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback